tirzepatide and crohn's disease Patients with stable inflammatory bowel (IBD) comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse Frontiers | GLP-1 and GLP-2

Clinical Evidence A study published in the New England Journal of Medicine followed 47 MCAS patients : 89% showed improvement in symptoms, including allergic, neurologic, digestive, and inflammation-related reactions Improvements happened within hours to days Only 13% experienced weight loss , and none became underweight Consistency is crucial

Stable blood sugar levels mean fewer insulin spikes and less fat storage

Unlike other types of batteries, its not a good idea just to run a LiPo until it dies

Studies report an inverse relationship between oxidative stress indicators and both glomerular filtration rate and dialysis duration (Terawaki et al., 2004)